Pear Therapeutics, Inc., Boston, MA 02109, USA.
University of Florida Health Sleep Disorders Center, FL 32606, USA.
J Comp Eff Res. 2021 May;10(7):569-581. doi: 10.2217/cer-2021-0004. Epub 2021 Mar 8.
Cognitive behavioral therapy for insomnia (CBT-I) is underused in healthcare settings and is challenging for people with insomnia to access because of uneven geographical distribution of behavioral sleep medicine providers. Prescription digital therapeutics can overcome these barriers. This study evaluates the effectiveness of a specific digital CBT-I therapeutic. igital eal-world vidence trial for dults with insomnia treated via obile (DREAM) is a 9-week, open-label, decentralized clinical trial to collect real-world evidence for a digital therapeutic (Somryst™) delivering CBT-I to patients with chronic insomnia. The primary objective is to examine the effectiveness of Somryst to reduce self-reported insomnia symptoms and severity in a real-world population (n = 350). This pragmatic study seeks to assess the potential benefits of treating insomnia with an asynchronous, mobile, tailored prescription digital therapeutic. NCT04325464 (ClinicalTrials.gov).
认知行为疗法治疗失眠症（CBT-I）在医疗保健环境中未得到充分应用，而且由于行为睡眠医学提供者的地理分布不均，失眠症患者难以获得这种疗法。处方数字疗法可以克服这些障碍。本研究评估了一种特定数字 CBT-I 疗法的有效性。igital 现实世界 vidence 试验治疗 dults 失眠症治疗通过 obile（DREAM）是一项为期 9 周的、开放标签的、去中心化的临床试验，旨在为一种数字疗法（Somryst™）收集现实世界的证据，该疗法为慢性失眠症患者提供 CBT-I。主要目的是在现实人群中（n=350）检查 Somryst 降低自我报告的失眠症状和严重程度的有效性。这项实用研究旨在评估使用异步、移动、定制的处方数字疗法治疗失眠症的潜在益处。NCT04325464（ClinicalTrials.gov）。
Zotero 插件